Voltaren Emulgel

Riik: Armeenia

keel: inglise

Allikas: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Laadi alla Toote omadused (SPC)
05-04-2016

Toimeaine:

diclofenac (diclofenac diethylamine)

Saadav alates:

Novartis Consumer Health S.A.

INN (Rahvusvaheline Nimetus):

diclofenac (diclofenac diethylamine)

Annus:

10mg/g

Ravimvorm:

gel for external use

Retsepti tüüp:

OTC

Toote omadused

                                Novartis Consumer Health
Global Regulatory Affairs
Global Labeling
VOLTAREN EMULGEL
Gel
Diclofenac diethylamine 1.16%
SMPC
The National Product Information (and Regional Product Information) is
based on the SmPC.
However, because national regulatory requirements and medical
practices vary between countries,
the National (and Regional) Product Information may differ in several
respects, including but not
limited to the Core Safety Information.
Author(s):
Babu Selvam
Document status:
FINAL
GLC approval date:
02 Dec 2010, 29 Sep 2011
GLC tracking ID:
2010 Dec 02/06-N, 2011-Sep-29/04-N
Amendment date(s):
3 Dec 2009, 17 Jun 2010, 18 Nov 2010, 02 Dec 2010, 29 Sep 2011
Effective date:
05 Oct 2011
Next update date:
Sep 2014
Number of pages:
7
Property of Novartis Consumer Health
Novartis
CONFIDENTIAL
Page 2
Voltaren DEA 1.16% range
TABLE OF CONTENTS
1
NAME OF THE MEDICINAL PRODUCT
.......................................................................3
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
.............................................3
3
PHARMACEUTICAL
FORM............................................................................................3
4
CLINICAL PARTICULARS
..............................................................................................3
4.1
Therapeutic
indications............................................................................................3
4.2
Posology and method of administration
..................................................................3
4.3
Contraindications
.....................................................................................................
4
4.4
Special warnings and precautions for
use................................................................4
4.5
Interaction with other medicinal products and other forms of
interaction ..............4
4.6
Pregnancy and
lactation...........................................................................................4
4.7
Effects on ability to drive and use machines
....................................
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik vene 17-04-2014

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu